Vutiglabridin - CAS 1800188-47-9

Vutiglabridin (HSG4112) is a novel and safe modulator of PON2, a racemic compound. vutiglabridin is an optimized structural analogue of Glabridin and is superior to Glabridin in terms of weight loss and chemical stability. vutiglabridin ameliorates mptp-induced neurodegeneration in Parkinson's disease mice by targeting mitochondrial paraoxonase-2. Vutiglabridin is a clinical phase 2 drug for the treatment of obesity and has therapeutic effects on p-mitochondrial PON2 in a PD model. vutiglabridin penetrates the brain, binds PON2, and restores 1-methyl-4-phenylpyridine (MPP*) -induced neuroblastoma in SH-SY5Y Vutiglabridin significantly attenuated 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) -induced dyskinesia and dopaminergic neuronal damage in mice modeled with PD in mouse experiments.

ROS, PPAR, Others, Phosphatase, Antibacterial

Others, Metabolism, Microbiology/Virology, DNA Damage/DNA Repair, Immunology/Inflammation

1800132

0.9907

C22H26O4

354.44

CC1(C)OC2=C(C3=C(CC(CO3)C4=C(O)C=C(OCC)C=C4)C=C2)CC1

-20°C

Ice Packs

Small Compound